Literature DB >> 7811870

Antibody-dependent enhancement of infection and the pathogenesis of viral disease.

D M Morens1.   

Abstract

Antibody-dependent enhancement of infection (ADE) is an in vitro serological phenomenon--or a group of phenomena--in which viral infection of susceptible cells is modified by the addition of virus-reactive antibody. Evidence suggests that ADE reflects immunologic processes that occur in vivo. Various severe and even fatal viral conditions of humans and animals, including dengue shock syndrome, the "early-death phenomenon" in experimental infections of immune animals, and other vaccine- and immunoglobulin-modified conditions, have been attributed to ADE by some researchers. ADE has caused great concern in relation to the development of vaccines against dengue virus and human immunodeficiency virus. More data are urgently needed on the mechanisms and determinants of ADE and on its alleged role in disease pathogenesis and in vaccine-associated phenomena.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7811870     DOI: 10.1093/clinids/19.3.500

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  95 in total

Review 1.  Perspectives for the treatment of infections with Flaviviridae.

Authors:  P Leyssen; E De Clercq; J Neyts
Journal:  Clin Microbiol Rev       Date:  2000-01       Impact factor: 26.132

Review 2.  Heterologous immunity between viruses.

Authors:  Raymond M Welsh; Jenny W Che; Michael A Brehm; Liisa K Selin
Journal:  Immunol Rev       Date:  2010-05       Impact factor: 12.988

3.  Public versus personal serotypes of a viral quasispecies.

Authors:  Lukas Hunziker; Adrian Ciurea; Mike Recher; Hans Hengartner; Rolf M Zinkernagel
Journal:  Proc Natl Acad Sci U S A       Date:  2003-05-02       Impact factor: 11.205

4.  Dengue 2 PDK-53 virus as a chimeric carrier for tetravalent dengue vaccine development.

Authors:  Claire Y-H Huang; Siritorn Butrapet; Kiyotaka R Tsuchiya; Natth Bhamarapravati; Duane J Gubler; Richard M Kinney
Journal:  J Virol       Date:  2003-11       Impact factor: 5.103

Review 5.  West Nile virus: a growing concern?

Authors:  L Hannah Gould; Erol Fikrig
Journal:  J Clin Invest       Date:  2004-04       Impact factor: 14.808

Review 6.  Dengue: defining protective versus pathologic immunity.

Authors:  Alan L Rothman
Journal:  J Clin Invest       Date:  2004-04       Impact factor: 14.808

7.  Replication-defective adenoviral vaccine vector for the induction of immune responses to dengue virus type 2.

Authors:  Smita Jaiswal; Navin Khanna; S Swaminathan
Journal:  J Virol       Date:  2003-12       Impact factor: 5.103

8.  Structural basis for Zika envelope domain III recognition by a germline version of a recurrent neutralizing antibody.

Authors:  Shannon R Esswein; Harry B Gristick; Andrea Jurado; Avery Peace; Jennifer R Keeffe; Yu E Lee; Alisa V Voll; Mohsan Saeed; Michel C Nussenzweig; Charles M Rice; Davide F Robbiani; Margaret R MacDonald; Pamela J Bjorkman
Journal:  Proc Natl Acad Sci U S A       Date:  2020-04-22       Impact factor: 11.205

9.  Attenuation markers of a candidate dengue type 2 vaccine virus, strain 16681 (PDK-53), are defined by mutations in the 5' noncoding region and nonstructural proteins 1 and 3.

Authors:  S Butrapet; C Y Huang; D J Pierro; N Bhamarapravati; D J Gubler; R M Kinney
Journal:  J Virol       Date:  2000-04       Impact factor: 5.103

10.  Impact of renal failure on the outcome of dengue viral infection.

Authors:  Mei-Chuan Kuo; Po-Liang Lu; Jer-Ming Chang; Ming-Yen Lin; Jih-Jin Tsai; Yen-Hsu Chen; Ko Chang; Hung-Chun Chen; Shang-Jyh Hwang
Journal:  Clin J Am Soc Nephrol       Date:  2008-07-30       Impact factor: 8.237

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.